Background: The increasing number of available point-of-care (POC) tests challenges clinicians regarding decisions on which tests to use, how to efficiently use them, and how to interpret the results. Although POC tests may offer benefits in terms of low turn-around-time, improved patient's satisfaction, and health outcomes, only few are actually used in clinical practice. Therefore, this study aims to identify which criteria are, in general, important in the decision to implement a POC test, and to determine their weight. Two POC tests available for use in Dutch general practices (i.e. the C-reactive protein (CRP) test and the glycated haemoglobin (HbA) test) serve as case studies. The information obtained from this study can be used to guide POC test development and their introduction in clinical practice.
Methods: Relevant criteria were identified based on a literature review and semi-structured interviews with twelve experts in the field. Subsequently, the criteria were clustered in four groups (i.e. user, organization, clinical value, and socio-political context) and the relative importance of each criterion was determined by calculating geometric means as implemented in the Analytic Hierarchy Process. Of these twelve experts, ten participated in a facilitated group session, in which their priorities regarding both POC tests (compared to central laboratory testing) were elicited.
Results: Of 20 criteria in four clusters, the test's clinical utility, its technical performance, and risks (associated with the treatment decision based on the test result) were considered most important for using a POC test, with relative weights of 22.2, 12.6 and 8.5%, respectively. Overall, the experts preferred the POC CRP test over its laboratory equivalent, whereas they did not prefer the POC HbA test. This difference was mainly explained by their strong preference for the POC CRP test with regard to the subcriterion 'clinical utility'.
Conclusions: The list of identified criteria, and the insights in their relative impact on successful implementation of POC tests, may facilitate implementation and use of existing POC tests in clinical practice. In addition, having experts score new POC tests on these criteria, provides developers with specific recommendations on how to increase the probability of successful implementation and use.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327588 | PMC |
http://dx.doi.org/10.1186/s12875-018-0893-4 | DOI Listing |
Small Methods
January 2025
Department of Chemistry, Rutgers University-Camden, Camden, NJ, 08102, USA.
Nucleic acid detection plays a crucial role in various applications, including disease diagnostics, research development, food safety, and environmental health monitoring. A rapid, point-of-care (POC) nucleic acid test can greatly benefit healthcare system by providing timely diagnosis for effective treatment and patient management, as well as supporting diseases surveillance for emerging pandemic diseases. Recent advancements in nucleic acids technology have led to rapid assays for single-stranded nucleic acids that can be integrated into simple and miniaturized platforms for ease of use.
View Article and Find Full Text PDFUrol Oncol
January 2025
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Urine is an attractive biospecimen for noninvasive tests to facilitate bladder tumor diagnostics. Three different point-of-care (POC) tests based on lateral flow immunoassays (LFAs) are currently commercially available: UBC® Rapid Test, BTA stat®, and NMP22 BladderChek. The present review discusses these different tests based on their performance, clinical utility and the nature of the respective analytes.
View Article and Find Full Text PDFLancet Public Health
January 2025
US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Background: Rapid, accessible, and accurate testing was paramount to an effective US COVID-19 response. Federal partners supported SARS-CoV-2 testing scale-up through an interagency-coordinated approach that focused on expanding supply chains, research and development, validation, and improving patient access. We aimed to provide an overview of the federal efforts to scale up the testing response and study the impact of scale-up.
View Article and Find Full Text PDFAm J Crit Care
January 2025
Shih-Hua Lin is a professor, Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei.
Background: Hyperkalemia can be detected by point-of-care (POC) blood testing and by artificial intelligence- enabled electrocardiography (ECG). These 2 methods of detecting hyperkalemia have not been compared.
Objective: To determine the accuracy of POC and ECG potassium measurements for hyperkalemia detection in patients with critical illness.
Front Bioeng Biotechnol
December 2024
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, United States.
Platelets are critical for blood clotting, with shear-induced platelet aggregation (SIPA) playing a key role in hemostasis and the prevention of excessive bleeding. SIPA function potentially leads to life-threatening diseases such as hemorrhage and myocardial infarction, which are leading causes of death globally. Point-of-care platelet function tests (POC PFTs) are developed to assess platelet dysfunction and distinguish between normal and abnormal platelet activity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!